Enterprise Value
222.3M
Cash
196.6M
Avg Qtr Burn
-16.47M
Short % of Float
9.65%
Insider Ownership
12.11%
Institutional Own.
81.92%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IVX-121 Details Respiratory syncytial virus | Phase 1/2 Interim update | |
IVX-A12 ( bivalent vaccine) Details Respiratory syncytial virus, Human metapneumovirus, Vaccine | Phase 1 Data readout | |
IVX-411 Details COVID-19 | Failed Discontinued |